Skip to main content
. 2021 Jul 2;14:4023–4037. doi: 10.2147/OTT.S312904

Figure 1.

Figure 1

CD19 and CD22 antigen expression on malignant B cells in the six R/R B-ALL patients. (A, C, E, G, I, K). High expression ofCD19 antigen on malignant B cells in the six R/R B-ALL patients before anti-CD19-CAR T cell therapy. (B, D, F, H, J, L). Normal or low expression of CD19 antigen, with high expression of CD22 antigen on malignant B cells in the six R/R B-ALL patients before anti-CD22-CAR T cell therapy.